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this entity as a diagnosis, in the sense of its being a defined medical condition. We did not intend by this to imply that one can rely strictly on these criteria to establish a diagnosis in clinical practice. In fact, we stated explicitly, "These classification criteria have limited use outside the arena of clinical research," to introduce the algorithm (in Fig. 2 of our article) for use in clinical practice.
The algorithm itself is a modification of one published by the correspondents and their colleagues, 1 but it was modified specifically to further emphasize the importance of weighing clinical data and post-test probabilities 2 and of applying clinical judgment to the diagnostic process. Moreover, the discussion of MRI findings includes mention of lesions that are not part of the classification criteria but that can be helpful in supporting a diagnosis in clinical practice. Finally, the Summary section in our article reemphasizes the potential difficulty in accurately establishing or ruling out a diagnosis of axial spondyloarthritis, with no mention of criteria. 
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Viral Load Kinetics of MERS Coronavirus Infection
To the Editor: The outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in South Korea involved 186 patients and resulted in 38 deaths, with four large hospital outbreaks accounting for 82% of the total cases. 1,2 Here, we report changes in viral load over time in patients with MERS.
We included all patients who were admitted to three Seoul National University-affiliated hospitals; the institutional review boards of these hospitals approved this study and waived the need for written informed consent on public health grounds. The patients were categorized into a group with severe disease (severe group) or a group with mild disease (mild group), depending on whether oxygen supplementation was used during the hospital stay. 3 Chest radiographs were scored as described previously (higher scores indicate greater involvement; see the Supplementary Appendix, available with the full text of this letter at NEJM.org). 4 Quantitative real-time reversetranscriptase polymerase chain reaction (rRT-PCR) for the envelope gene (upE) was performed with the PowerChek MERS Real-time PCR kit (Kogenebiotech). A generalized mixed model with binary outcome was used to compare repeated samples.
A total of 17 patients were included in the study. The median incubation period was 7 days (range, 2 to 14). Nine patients were categorized into the severe group; in these patients, the chest radiograph score increased abruptly during week 2 and reached a peak at approximately day 14 ( Fig. S1A in the Supplementary Appendix) . The copies of MERS-CoV RNA detected by rRT-PCR in respiratory samples peaked during week 2, and the median value was 7.21 log 10 copies per milliliter in the severe group and 5.54 log 10 copies per milliliter in the mild group (P = 0.06). The peak in viral load in sputum or tracheal aspirate was higher and occurred later in the severe group than in the mild group (Fig. 1A ). An RNA level exceeding 10 5 copies per milliliter in throat-swab samples was found in all 9 patients in the severe group and in 1 of 8 patients (12%) in the mild group (P<0.001) ( Fig. 1B) . At the time of the initial presentation, MERS-CoV RNA was detected in the nasopharyngeal-swab specimens from 5 of The copies of Middle East respiratory syndrome coronavirus (MERS-CoV) RNA (upE) in sputum or tracheal aspirate (Panel A) and throat-swab specimens (Panel B) were estimated by means of real-time reverse-transcriptase polymerase chain reaction. The patients in the severe group were those who received oxygen supplementation or mechanical ventilation, whereas the patients in the mild group were those who did not require oxygen supplementation. The dashed line indicates the detection limit. Different color-symbol combinations denote individual patients; blue symbols denote patients in the severe group, and orange symbols patients in the mild group. Data points below the limit of detection are shown at different levels for clarity. 17 patients (29%) and in the throat-swab specimens of 10 of 17 patients (59%) (P = 0.03) ( Fig.  1B, and Fig. S1B in the Supplementary Appendix). Among paired swab specimens obtained from the nasopharynges and throats of the 17 patients, MERS-CoV RNA was detected in 8 of 70 (11%) nasopharyngeal-swab specimens and in 29 of 70 (41%) throat-swab specimens (P<0.001). Viral RNA was detected in serum samples from 3 of 9 patients (33%) in the severe group and in 1 of 8 patients (12%) in the mild group at initial presentation (P = 0.58) (Fig. S1C in the Supplementary Appendix).
We found that the viral loads in the severe group were higher than those in the mild group. The patients in the severe group also had more prolonged viral shedding in respiratory secretions, beyond 21 days after the onset of symptoms, whereas viral RNA was no longer detected by 21 days in the mild group. A similar association between higher viral load and worse outcome was observed in the severe acute respiratory syndrome (SARS). 5 In conclusion, MERS-CoV concentrations peaked during the second week of illness. Lower respiratory tract specimens had higher and more prolonged levels of MERS-CoV RNA as detected by rRT-PCR; throat swabs may be an alternative source of diagnostic samples, especially when sputum cannot be obtained. Myoung-don Oh, M.D., Ph.D. Wan Beom Park, M.D., Ph.D. Pyoeng Gyun Choe, M.D.
